IQVIA Holdings Inc. (NYSE:IQV) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received a consensus rating of “Moderate Buy” from the nineteen analysts that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $259.13.

A number of research firms have commented on IQV. TD Cowen reduced their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, November 1st. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Truist Financial cut their target price on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

IQVIA Price Performance

IQVIA stock opened at $192.68 on Tuesday. The stock’s 50 day moving average price is $226.95 and its two-hundred day moving average price is $228.29. The stock has a market capitalization of $34.97 billion, a price-to-earnings ratio of 25.28, a PEG ratio of 2.17 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a 52-week low of $189.63 and a 52-week high of $261.73.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. MidWestOne Financial Group Inc. lifted its stake in IQVIA by 5.1% in the third quarter. MidWestOne Financial Group Inc. now owns 4,786 shares of the medical research company’s stock valued at $1,134,000 after purchasing an additional 232 shares during the last quarter. Continuum Advisory LLC lifted its position in shares of IQVIA by 13.1% during the 3rd quarter. Continuum Advisory LLC now owns 1,739 shares of the medical research company’s stock valued at $412,000 after buying an additional 201 shares during the last quarter. LRI Investments LLC grew its stake in shares of IQVIA by 3,542.7% during the 3rd quarter. LRI Investments LLC now owns 23,823 shares of the medical research company’s stock worth $5,645,000 after acquiring an additional 23,169 shares during the period. Drucker Wealth 3.0 LLC increased its holdings in IQVIA by 1.4% in the 3rd quarter. Drucker Wealth 3.0 LLC now owns 9,260 shares of the medical research company’s stock worth $2,194,000 after acquiring an additional 124 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. raised its stake in IQVIA by 7.7% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 54,164 shares of the medical research company’s stock valued at $12,835,000 after acquiring an additional 3,872 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.